New combo therapy shows promise for tough rectal cancer

NCT ID NCT07005570

Recruiting now Disease control Sponsor: Dechang Diao Source: ClinicalTrials.gov ↗

First seen Feb 01, 2026 · Last updated May 06, 2026 · Updated 5 times

Summary

This study tests whether adding an immunotherapy drug (PD-1 monoclonal antibody) and a targeted therapy (bevacizumab) to standard short-course radiation and chemotherapy can improve outcomes for people with a specific type of locally advanced rectal cancer (pMMR/MSS). About 86 participants will be randomly assigned to receive the standard treatment with or without the two extra drugs. The main goal is to see if the new combination leads to a higher rate of complete cancer disappearance (complete response) after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PMMR/MSS LOCALLY ADVANCED RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sixth Affiliated Hospital, Sun Yat-sen University
RECRUITING

Guangzhou, Guangdong, 610655, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

PMMR/MSS LOCALLY ADVANCED RECTAL CANCER